EVERY SAMPLE COUNTS. EVERY INSIGHT COUNTS.
Knowledge is our weapon against Coronavirus – and insights into how SARS-CoV-2 works is what AYOXXA can offer the scientific community.
Rapid and accurate profiling of biomarker signatures in clinical samples is increasingly important to monitoring therapeutic interventions. Such an approach may prove relevant for COVID-19 as well. A study published in The Lancet (1,2) provides preliminary evidence that cytokine release syndrome (CRS) – also called “cytokine storm” – may play a role in severe cases of the new disease. Such cases exhibit acute respiratory distress syndrome (ARDS), which can be triggered by a cascade of hyperinflammatory events and excessive cytokine release leading eventually to multi-organ failure and death.
The LUNARIS platform enables monitoring of the “cytokine storm”. Clinical samples (e.g., serum, plasma, saliva etc.) as small as 3 µL in volume can be simultaneously analyzed to quantify up to 12 biomarkers (or more) with high precision and sensitivity in simple workflow for up to 384 samples.
- Identify biomarker signatures associated with severe COVID-19
- Elucidate disease mechanisms and find potential therapy targets
- Uncover molecular signals that can help guide treatment options
AYOXXA has been working with global leaders in clinical research (3) to better understand CRS in the context of several diseases and therapeutic interventions. Our know-how, expertise and tools can open new avenues to contain SARS-CoV-2 and save lives as COVID-19 cases continue to rise over the coming weeks.
Call us. Tell us how we can advance your work.
1 Mehta et al., Lancet. 2020 Mar 16, pii: S0140-6736(20)30628-0.
2 Huang et al., Lancet. 2020 Feb 15; 395(10223):497-506.
3 Karantanos et al., Bone Marrow Transplant. 2019 Oct 2; doi: 10.1038/s41409-019-0707-x.